Haemonetics Fully Launches Vascade MVP XL Vascular Closure System

Haemonetics began the full market release of its Vascade MVP XL mid-bore venous closure system.
 
Vascade MVP XL features collapsible disc technology and a proprietary, resorbable collagen patch to promote quick hemostasis. It uses 58% more collagen and a larger disc that the company’s Vascade MVP system. This provides a more robust closure solutions for surgeries needing 10-12 Fr sheaths (up to 15 Fr in outer diameter), like cryoblation, pulsed field ablation (PFA), and left atrial appendage closure (LAAC).
 
Vascade was released on a limited basis in June and has since been used by about 80 physicians at over 30 hospitals in multiple types of procedures.
 
“We received overwhelmingly positive feedback during our limited market release and we are excited to make VASCADE MVP XL available to physicians at all U.S. hospitals as soon as possible,” said Stew Strong, President, Global Hospital at Haemonetics. “With our full market release underway and an ongoing clinical trial program to broaden the indications for this device to even larger access points, VASCADE MVP XL will complement our Interventional Technologies portfolio, and underscore our aspiration to be the go-to leader in vascular closure.”
 
The company’s Vascade portfolio includes the Vascade system for small-bore arterial and venous closure with standard 5-6/7 Fr procedural sheaths. The Vascade MVP system is for mid-bore multi-access femoral venous closure with 6-12 Fr ID procedural sheaths.
 
In April, Haemonetics gained U.S. Food and Drug Administration (FDA) 510(k) clearance for its TEG 6s hemostasis analyzer system Global Hemostasis-HN assay cartridge.